Clincosm LogoSign in Get a demo

melanoma

Showing NaN - NaN of 175
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Worldwide (relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab)

Not yet recruiting
  • Melanoma
  • Anchorage, Alaska
  • +28 more
Oct 20, 2023

Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma Trial in United States (MT-8421, Nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +10 more
  • Los Angeles, California
  • +4 more
Sep 5, 2023

Melanoma Trial in United States (IO102/IO103, Nivolumab-Relatlimab)

Recruiting
  • Melanoma
  • Basking Ridge, New Jersey
  • +6 more
Jun 23, 2023

Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma Trial in United States (MQ719,

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • +18 more
  • Basking Ridge, New Jersey
  • +6 more
May 18, 2023

Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma Trial in United States

Recruiting
  • Invasive Ductal Breast Carcinoma
  • +14 more
  • Stereotactic body radiotherapy
  • Lattice Radiation Therapy
  • Basking Ridge, New Jersey
  • +6 more
Apr 20, 2023

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

Recruiting
  • Colorectal Carcinoma
  • +21 more
  • Dual X-ray Absorptiometry
  • +2 more
  • Birmingham, Alabama
  • +18 more
Jan 30, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +39 more
Jan 25, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +28 more
Jan 25, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +4 more
  • Los Angeles, California
  • +34 more
Jan 25, 2023

Melanoma, Colorectal Cancer, Non-Small-Cell Lung Cancer Trial in Springdale, Nashville (PF-07799933, binimetinib, cetuximab)

Recruiting
  • Melanoma
  • +4 more
  • Fayetteville, Arkansas
  • +23 more
Jan 19, 2023

Melanoma Trial in New York (Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs))

Completed
  • Melanoma
  • Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 12, 2023

Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)

Recruiting
  • Melanoma
  • +4 more
  • Pembrolizumab
  • Aurora, Colorado
  • +18 more
Jan 5, 2023

Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))

Completed
Has Results
  • Ovarian Cancer
  • +7 more
  • Enapotamab vedotin (HuMax-AXL-ADC)
  • Phoenix, Arizona
  • +40 more
Dec 12, 2022

Solid Tumors, Melanoma, NSCLC Trial in France, Spain, United States (CFT1946, Trametinib)

Recruiting
  • Solid Tumors
  • +4 more
  • Boston, Massachusetts
  • +9 more
Dec 19, 2022

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

NSCLC, Ovarian Cancer, Melanoma Trial in Worldwide (LXH254, PDR001)

Terminated
  • NSCLC
  • +3 more
  • Boston, Massachusetts
  • +17 more
Dec 20, 2022

Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)

Recruiting
  • Small Cell Lung Cancer
  • +8 more
  • Chandler, Arizona
  • +65 more
Dec 19, 2022

Melanoma Trial in Worldwide (Ceralasertib, Durvalumab)

Recruiting
  • Melanoma
  • Los Angeles, California
  • +75 more
Dec 5, 2022

Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)

Recruiting
  • Melanoma
  • Nivolumab
  • Nivolumab + Relatlimab Fixed Dose Combination
  • Birmingham, Alabama
  • +185 more
Dec 3, 2022

Melanoma, Neuroblastoma, Sarcoma Trial in New York (124I-Humanized 3F8)

Active, not recruiting
  • Melanoma
  • +2 more
  • 124I-Humanized 3F8
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 1, 2022

Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer Trial in United States (NC318)

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • +8 more
  • Los Angeles, California
  • +5 more
Nov 29, 2022

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
Has Results
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022